{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:52:34Z","timestamp":1789638754480,"version":"4.0.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medical University of Gdansk","award":["ST 01-10023\/0004989\/01182\/0\/2025"],"award-info":[{"award-number":["ST 01-10023\/0004989\/01182\/0\/2025"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,29]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Although pre- and post-transplant dyslipidaemia is one of the most prevalent modifiable risk factors associated with an increased risk of major cardiovascular events, it remains underdiagnosed and undertreated. Moreover, the risk of cardiovascular events, acute allograft rejection and vasculopathy associated with dyslipidaemia is underestimated. Although the most prominent underlying cause of dyslipidaemia in solid organ transplant (SOT) recipients is immunosuppressants, their adjustment should be done with caution to avoid an acute graft rejection. Dietary intervention and lipid-lowering therapy (LLT) are needed to lower low-density lipoprotein cholesterol (LDL-C) and triglycerides and to improve the outcomes. Although statins are first-line drugs, non-adherence, interactions with immunosuppressants and the concern related to polypharmacy impact statin use in SOT patients. The evolving evidence on combination therapy with statin and ezetimibe, novel PCSK9 modulators and bempedoic acid indicate that LDL-C can be safely and efficiently reduced with improved adherence. Since SOT patients are complex, a structured multidisciplinary team approach can deliver comprehensive lipid management, improve patient care and prevent potential complications. A call to action is needed for further trials and registries to determine potential benefits of strategy based on initial combination therapy with ezetimibe and a low\/moderate dose of statin, as well as novel LLT. Optimal lipid treatment targets in SOT recipients should be determined, depending on the transplanted organ and cardiovascular risk category. We aimed to review current and future management of lipid disorders, propose an algorithm useful in clinical practice and call attention to broader use of novel LLTs along with further studies to assess their impact on clinical outcomes.<\/jats:p>","DOI":"10.1093\/ndt\/gfaf104","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T05:04:49Z","timestamp":1751000689000},"page":"1659-1671","source":"Crossref","is-referenced-by-count":8,"title":["Lipid-lowering agents in solid organ transplant recipients"],"prefix":"10.1093","volume":"40","author":[{"given":"Agnieszka","family":"Mickiewicz","sequence":"first","affiliation":[{"name":"Medical University of Gdansk First Department of Cardiology, , Gdansk ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u0142awomir","family":"\u017begle\u0144","sequence":"additional","affiliation":[{"name":"Medical University of Gdansk Department of Pneumonology and Allergology, , Gdansk,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5853-2147","authenticated-orcid":false,"given":"Karolina","family":"K\u0119dzierska-Kapuza","sequence":"additional","affiliation":[{"name":"National Medical Institute of the Ministry of Interior Affairs and Administration Department of Internal Medicine, Endocrinology and Diabetology, , Warsaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zbigniew","family":"Heleniak","sequence":"additional","affiliation":[{"name":"Medical University of Gdansk Department of Nephrology, Transplantology and Internal Medicine, , Gdansk ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Frankiewicz","sequence":"additional","affiliation":[{"name":"Medical University of Gdansk First Department of Cardiology, , Gdansk ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Adamczyk","sequence":"additional","affiliation":[{"name":"Medical University of Warsaw Department of Transplantation Medicine, Nephrology and Internal Diseases, , Warsaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"We\u0142nicki","sequence":"additional","affiliation":[{"name":"Medical University of Warsaw 3rd Department of Internal Diseases and Cardiology at the \u00a0 Warsaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Wawrzynowicz-Syczewska","sequence":"additional","affiliation":[{"name":"Pomeranian Medical University Department of Infectious Diseases, Hepatology and Liver Transplantation, , Szczecin ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Raszeja-Wyszomirska","sequence":"additional","affiliation":[{"name":"Medical University of Warsaw Department of Hepatology, Transplantology, and Internal Medicine, , Warsaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Durlik","sequence":"additional","affiliation":[{"name":"Medical University of Warsaw Department of Transplantation Medicine, Nephrology and Internal Diseases, , Warsaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[{"name":"Medical University of Lodz Department of Preventive Cardiology and Lipidology, , Lodz ,","place":["Poland"]},{"name":"Polish Mother's Memorial Hospital Research Institute Department of Cardiology and Congenital Diseases of Adults, , Lodz ,","place":["Poland"]},{"name":"Johns Hopkins University School of Medicine Ciccarone Center for the Prevention of Cardiovascular Disease, , Baltimore, MD ,","place":["USA"]},{"name":"Cardiovascular Research Centre , Zielona G\u00f3ra , and","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicja","family":"D\u0119bska-\u015alizie\u0144","sequence":"additional","affiliation":[{"name":"Medical University of Gdansk Department of Nephrology, Transplantology and Internal Medicine, , Gdansk ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Grucha\u0142a","sequence":"additional","affiliation":[{"name":"Medical University of Gdansk First Department of Cardiology, , Gdansk ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Malyszko","sequence":"additional","affiliation":[{"name":"Medical University of Warsaw Department of Nephrology, Dialysis and Internal Medicine, , Warsaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"key":"2025082900421737600_bib1","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jacl.2019.01.011","article-title":"Management of dyslipidemia in adult solid organ transplant recipients","volume":"13","author":"Warden","year":"2019","journal-title":"J Clin Lipidol"},{"key":"2025082900421737600_bib2","doi-asserted-by":"publisher","first-page":"e13794","DOI":"10.1111\/ctr.13794","article-title":"Cardiac allograft vasculopathy: insights on pathogenesis and therapy","volume":"34","author":"Lee","year":"2020","journal-title":"Clin Transplant"},{"key":"2025082900421737600_bib3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2025082900421737600_bib4","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/phar.2716","article-title":"Consensus recommendations for use of maintenance immunosuppression in solid organ transplantation: endorsed by the American College of Clinical Pharmacy, American Society of Transplantation, and the International Society for Heart and Lung Transplantation","volume":"42","author":"Nelson","year":"2022","journal-title":"Pharmacotherapy"},{"key":"2025082900421737600_bib5","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.arbres.2021.04.016","article-title":"Value of preoperative use of statins as a protective factor for severe graft dysfunction after lung transplantation: a multicenter propensity score analysis","volume":"57","author":"Bello","year":"2021","journal-title":"Arch Bronconeumol"},{"key":"2025082900421737600_bib6","first-page":"355","article-title":"Lipid apheresis after heart transplantation\u2014the Dresden experience","volume-title":"Transplantationsmedizi","author":"Julius","year":"2010"},{"key":"2025082900421737600_bib7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3390\/diseases6030063","article-title":"Inclisiran: a new promising agent in the management of hypercholesterolemia","volume":"6","author":"Kosmas","year":"2018","journal-title":"Diseases"},{"key":"2025082900421737600_bib8","first-page":"1457","article-title":"An observational study of ezetimibe in cardiac transplant recipients receiving calcineurin inhibitors","author":"Makkar","year":"2013"},{"key":"2025082900421737600_bib9","doi-asserted-by":"publisher","first-page":"1284562","DOI":"10.3389\/fcvm.2024.1284562","article-title":"The role of structured inpatient lipid protocols in optimizing non-statin lipid lowering therapy: a review and single-center experience","volume":"11","author":"Gier","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"2025082900421737600_bib10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11883-024-01271-x","article-title":"Inclisiran, reasons for a novel agent in a crowded therapeutic field","volume":"27","author":"Di Giacomo-Barbagallo","year":"2024","journal-title":"Curr Atheroscler Rep"},{"key":"2025082900421737600_bib11","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"2025082900421737600_bib12","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/j.jchf.2024.04.026","article-title":"Randomized trial of cholesterol lowering with evolocumab for cardiac allograft vasculopathy in heart transplant recipients","volume":"12","author":"Broch","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2025082900421737600_bib13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/eurheartj\/ehac594","article-title":"Inclisiran and cardiovascular events: a patient-level analysis of phase III trials","volume":"44","author":"Ray","year":"2023","journal-title":"Eur Heart J"},{"key":"2025082900421737600_bib14","doi-asserted-by":"publisher","first-page":"11313","DOI":"10.3389\/ti.2023.11313","article-title":"Novel therapeutic strategies for dyslipidemia: first report of inclisiran therapy in a kidney transplanted patient","volume":"36","author":"Ueberdiek","year":"2023","journal-title":"Transpl Int"},{"key":"2025082900421737600_bib15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S0007114514003341","article-title":"Effects of the Dietary Approach to Stop Hypertension (DASH) diet on cardiovascular risk factors: a systematic review and meta-analysis","volume":"113","author":"Siervo","year":"2015","journal-title":"Br J Nutr"},{"key":"2025082900421737600_bib16","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12937-018-0337-y","article-title":"Adherence to Mediterranean and low-fat diets among heart and lung transplant recipients: a randomized feasibility study","volume":"17","author":"Entwistle","year":"2018","journal-title":"Nutr J"},{"key":"2025082900421737600_bib17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1399-0012.2008.00915.x","article-title":"Role of dietary intervention and nutritional follow-up in heart transplant recipients","volume":"23","author":"Guida","year":"2009","journal-title":"Clin Transplant"},{"key":"2025082900421737600_bib18","doi-asserted-by":"publisher","first-page":"e13594","DOI":"10.1111\/eci.13594","article-title":"Statin use and incident cardiovascular events in renal transplant recipients","volume":"51","author":"Anderson","year":"2021","journal-title":"Eur J Clin Invest"},{"key":"2025082900421737600_bib19","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1002\/ehf2.12784","article-title":"Statin intensity and risk for cardiovascular events after heart transplantation","volume":"7","author":"Golbus","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2025082900421737600_bib20","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.healun.2022.10.015","article-title":"The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients","volume":"42","author":"Velleca","year":"2023","journal-title":"J Heart Lung Transplant"},{"issue":"4 Suppl","key":"2025082900421737600_bib21","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"key":"2025082900421737600_bib22","doi-asserted-by":"publisher","first-page":"e075837","DOI":"10.1136\/bmj-2023-075837","article-title":"Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial","volume":"383","author":"Lee","year":"2023","journal-title":"BMJ"},{"key":"2025082900421737600_bib23","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1681\/ASN.2022020135","article-title":"Association of rosuvastatin use with risk of hematuria and proteinuria","volume":"33","author":"Shin","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2025082900421737600_bib24","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy\u2014European Atherosclerosis Society consensus panel statement on assessment, aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"2025082900421737600_bib25","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ahj.2010.08.012","article-title":"Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease","volume":"160","author":"Baigent","year":"2010","journal-title":"Am Heart J"},{"key":"2025082900421737600_bib26","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/S0140-6736(22)00916-3","article-title":"Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial","volume":"400","author":"Kim","year":"2022","journal-title":"Lancet"},{"key":"2025082900421737600_bib27","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1093\/annonc\/mdu492","article-title":"Pharmacokinetic interaction involving fenofibrate and everolimus","volume":"26","author":"Mir","year":"2015","journal-title":"Ann Oncol"},{"key":"2025082900421737600_bib28","doi-asserted-by":"publisher","first-page":"S0033-0620(24)00168-3","DOI":"10.1016\/j.pcad.2024.11.003","article-title":"Omega-3 and risk of atrial fibrillation: vagally-mediated double-edged sword","author":"O'Keefe","year":"2024","journal-title":"Prog Cardiovasc Dis"},{"key":"2025082900421737600_bib29","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.3390\/jcm11113247","article-title":"Proprotein convertase subtilisin\/kexin type 9 inhibitors use for atherogenic dyslipidemia in solid organ transplant patients","volume":"11","author":"Cuomo","year":"2022","journal-title":"J Clin Med"},{"key":"2025082900421737600_bib30","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s11883-025-01299-7","article-title":"Oral PCSK9 inhibitors: will they work?","volume":"27","author":"Tokg\u00f6zo\u011flu","year":"2025","journal-title":"Curr Atheroscler Rep"},{"key":"2025082900421737600_bib31","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.jacc.2018.10.039","article-title":"Alirocumab reduces total nonfatal cardiovascular and fatal events: the ODYSSEY OUTCOMES trial","volume":"73","author":"Szarek","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2025082900421737600_bib32","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1001\/jamacardio.2019.0886","article-title":"Effect of the PCSK9 inhibitor evolocumab on total cardiovascular events in patients with cardiovascular disease: a prespecified analysis from the FOURIER Trial","volume":"4","author":"Murphy","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2025082900421737600_bib33","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s10557-022-07413-0","article-title":"Efficacy and safety of inclisiran in patients with polyvascular disease: pooled, post hoc analysis of the ORION-9, ORION-10, and ORION-11 phase 3 randomized controlled trials","volume":"38","author":"Koenig","year":"2024","journal-title":"Cardiovasc Drugs Ther"},{"key":"2025082900421737600_bib34","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1093\/cvr\/cvae109","article-title":"Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial","volume":"120","author":"Wright","year":"2024","journal-title":"Cardiovasc Res"},{"key":"2025082900421737600_bib35","doi-asserted-by":"publisher","first-page":"e515","DOI":"10.1016\/j.jacl.2024.04.045","article-title":"Treatment patterns among early inclisiran vs anti-PCSK9 mAbs users: a retrospective analysis of US claims databases","volume":"18","author":"Popadic","year":"2024","journal-title":"J Clin Lipidol"},{"key":"2025082900421737600_bib36","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/eurheartj\/ehae781","article-title":"Olpasiran lowering of lipoprotein(a) according to baseline levels: insights from the OCEAN(a)-DOSE study","volume":"46","author":"Kaur","year":"2025","journal-title":"Eur Heart J"},{"key":"2025082900421737600_bib37","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.jacc.2021.12.032","article-title":"Effect of pelacarsen on lipoprotein(a) cholesterol and corrected low-density lipoprotein cholesterol","volume":"79","author":"Yeang","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2025082900421737600_bib38","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1038\/s41598-024-51782-5","article-title":"Lipoprotein apheresis affects the concentration of extracellular vesicles in patients with elevated lipoprotein (a)","volume":"14","author":"Marl\u0119ga-Linert","year":"2024","journal-title":"Sci Rep"},{"key":"2025082900421737600_bib39","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"2025082900421737600_bib40","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.5114\/aoms\/141941","article-title":"PoLA\/CFPiP\/PCS\/PSLD\/PSD\/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021","volume":"17","author":"Banach","year":"2021","journal-title":"Arch Med Sci"},{"key":"2025082900421737600_bib41","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.cjca.2019.12.025","article-title":"Canadian Cardiovascular Society\/Canadian Cardiac Transplant Network position statement on heart transplantation: patient eligibility, selection, and post-transplantation care","volume":"36","author":"Chih","year":"2020","journal-title":"Can J Cardiol"},{"key":"2025082900421737600_bib42","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/petr.12095","article-title":"Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients","volume":"17","author":"Kobayashi","year":"2013","journal-title":"Pediatr Transplant"},{"key":"2025082900421737600_bib43","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/j.healun.2004.08.014","article-title":"Survival, graft atherosclerosis, and rejection incidence in heart transplant recipients treated with statins: 5-year follow-up","volume":"24","author":"Stojanovic","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"2025082900421737600_bib44","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3390\/transplantology3020020","article-title":"Dyslipidemia in renal transplant recipients","volume":"3","author":"Chmielnicka","year":"2022","journal-title":"Transplantology"},{"key":"2025082900421737600_bib45","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1111\/j.1600-6143.2005.01105.x","article-title":"Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study","volume":"5","author":"Holdaas","year":"2005","journal-title":"Am J Transplant"},{"key":"2025082900421737600_bib46","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1159\/000112225","article-title":"Effects of renal replacement therapy on plasma lipoprotein(a) levels","volume":"28","author":"Rosas","year":"2008","journal-title":"Am J Nephrol"},{"key":"2025082900421737600_bib47","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1476-511X-12-53","article-title":"Pretransplant dyslipidaemia determines outcome in lung transplant recipients","volume":"12","author":"Wenger","year":"2013","journal-title":"Lipids Health Dis"},{"key":"2025082900421737600_bib48","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.3748\/wjg.v26.i19.2374","article-title":"Predicting dyslipidemia after liver transplantation: a significant role of recipient metabolic inflammation profile","volume":"26","author":"Huang","year":"2020","journal-title":"World J Gastroenterol"},{"key":"2025082900421737600_bib49","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/s41598-020-79673-5","article-title":"An observational study on the effect of hypercholesterolemia developed after living donor liver transplantation on cardiac event and graft failure","volume":"11","author":"Park","year":"2021","journal-title":"Sci Rep"},{"key":"2025082900421737600_bib50","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40842-016-0032-x","article-title":"Diabetes and other endocrine-metabolic abnormalities in the long-term follow-up of pancreas transplantation","volume":"2","author":"Lauria","year":"2016","journal-title":"Clin Diabetes Endocrinol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfaf104\/63509333\/gfaf104.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/9\/1659\/63509333\/gfaf104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/9\/1659\/63509333\/gfaf104.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T04:42:26Z","timestamp":1756442546000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/40\/9\/1659\/8165686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":50,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,6,17]]},"published-print":{"date-parts":[[2025,8,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaf104","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,6,17]]}}}